Voyager Therapeutics (VYGR) Research & Development (2016 - 2025)
Historic Research & Development for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $35.9 million.
- Voyager Therapeutics' Research & Development rose 1860.06% to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.3 million, marking a year-over-year increase of 1426.23%. This contributed to the annual value of $127.4 million for FY2024, which is 3818.51% up from last year.
- Per Voyager Therapeutics' latest filing, its Research & Development stood at $35.9 million for Q3 2025, which was up 1860.06% from $31.3 million recorded in Q2 2025.
- In the past 5 years, Voyager Therapeutics' Research & Development ranged from a high of $35.9 million in Q3 2025 and a low of $12.5 million during Q2 2022
- Its 5-year average for Research & Development is $23.8 million, with a median of $22.3 million in 2021.
- Its Research & Development has fluctuated over the past 5 years, first tumbled by 3626.11% in 2021, then surged by 7700.5% in 2023.
- Quarter analysis of 5 years shows Voyager Therapeutics' Research & Development stood at $14.0 million in 2021, then grew by 3.79% to $14.6 million in 2022, then skyrocketed by 77.01% to $25.8 million in 2023, then surged by 38.15% to $35.6 million in 2024, then rose by 0.8% to $35.9 million in 2025.
- Its Research & Development was $35.9 million in Q3 2025, compared to $31.3 million in Q2 2025 and $31.5 million in Q1 2025.